ID29818A - Penggunaan antagonis reseptor angiotensin ii untuk mengobati infarksi miokardial - Google Patents

Penggunaan antagonis reseptor angiotensin ii untuk mengobati infarksi miokardial

Info

Publication number
ID29818A
ID29818A IDW00200101602A ID20011602A ID29818A ID 29818 A ID29818 A ID 29818A ID W00200101602 A IDW00200101602 A ID W00200101602A ID 20011602 A ID20011602 A ID 20011602A ID 29818 A ID29818 A ID 29818A
Authority
ID
Indonesia
Prior art keywords
angiotensin
treat
receptor antagonists
miocardial infarction
acute
Prior art date
Application number
IDW00200101602A
Other languages
English (en)
Inventor
Jessica M Mann
Pascale Oddou
Eric Michel Neuhart
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26153740&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID29818(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ID29818A publication Critical patent/ID29818A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IDW00200101602A 1999-01-26 2000-01-24 Penggunaan antagonis reseptor angiotensin ii untuk mengobati infarksi miokardial ID29818A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99810061 1999-01-26
US46866499A 1999-12-21 1999-12-21

Publications (1)

Publication Number Publication Date
ID29818A true ID29818A (id) 2001-10-11

Family

ID=26153740

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW00200101602A ID29818A (id) 1999-01-26 2000-01-24 Penggunaan antagonis reseptor angiotensin ii untuk mengobati infarksi miokardial

Country Status (25)

Country Link
EP (2) EP1714651A1 (id)
JP (1) JP2002535367A (id)
KR (1) KR100674053B1 (id)
CN (1) CN1337879A (id)
AT (1) ATE330599T1 (id)
AU (1) AU766453C (id)
BR (1) BR0007686A (id)
CA (1) CA2360691A1 (id)
CY (1) CY1105257T1 (id)
CZ (1) CZ20012682A3 (id)
DE (1) DE60028928T2 (id)
DK (1) DK1146872T3 (id)
ES (1) ES2265910T3 (id)
HK (1) HK1041808B (id)
HU (1) HUP0105199A3 (id)
ID (1) ID29818A (id)
IL (2) IL144216A0 (id)
NO (1) NO20013459L (id)
NZ (1) NZ513039A (id)
PL (1) PL197161B1 (id)
PT (1) PT1146872E (id)
RU (2) RU2298405C2 (id)
SI (1) SI1146872T1 (id)
SK (1) SK10522001A3 (id)
WO (1) WO2000044378A1 (id)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100646716B1 (ko) 1998-12-23 2006-11-17 노파르티스 아게 Ａｔ-1 또는 ａｔ-2 수용체의 증가와 관련된 질환의치료에 있어서 ａｔ-1 수용체 길항제 또는 ａｔ-2 수용체조절제의 용도
AU2001284413A1 (en) * 2000-08-30 2002-03-13 Sankyo Company Limited Medicinal compositions for preventing or treating heart failure
US7076287B2 (en) 2000-12-29 2006-07-11 Ge Medical Systems Information Technologies, Inc. System and method for detecting new left bundle branch block for accelerating treatment of acute myocardial infarction
US20040266836A1 (en) * 2001-10-18 2004-12-30 Peter Buhlmayer Organic compounds
WO2003097099A1 (en) * 2002-05-17 2003-11-27 Novartis Ag Combination of angiotensin ii receptor blocker and beta-blocker for secondary prevention of myocardial infarction
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
SE0302331D0 (sv) * 2003-08-29 2003-08-29 Astrazeneca Ab New use II
WO2005030202A1 (en) * 2003-09-26 2005-04-07 Novartis Ag Use of angiotensin ii receptor antagonists for treating cerebrovascular disorders
WO2005053687A1 (en) * 2003-11-25 2005-06-16 Novartis Ag Combination of organic compounds
WO2009087116A1 (en) * 2008-01-11 2009-07-16 Novartis Ag Use of spp100 for the treatment of acute mi
CN104086623B (zh) * 2014-07-02 2017-05-24 牡丹江友搏药业有限责任公司 一种新的具有降压和细胞保护作用的化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027208D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
EP0577025A3 (de) * 1992-07-01 1998-02-04 Hoechst Aktiengesellschaft Angiotensin-II-Rezeptorantagonisten zur Behandlung und Prophylaxe von koronaren Herzerkrankungen
FR2716882B1 (fr) * 1994-03-04 1996-04-05 Roussel Uclaf Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.
FR2716883B1 (fr) * 1994-03-04 1996-04-26 Roussel Uclaf Nouveaux dérivés tétrasubstitués de l'imidazole, leur préparation, nouveaux intermédiaires obtenus, leur application à titre de médicaments, compositions pharmaceutiques les renfermant.
DE4432860A1 (de) * 1994-09-15 1996-03-21 Merck Patent Gmbh Imidazopyridine
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US5795904A (en) * 1996-12-06 1998-08-18 Merck & Co., Inc. Enhanced functional recovery of the heart by losartan treatment after an ischemic attach

Also Published As

Publication number Publication date
ATE330599T1 (de) 2006-07-15
SI1146872T1 (sl) 2006-12-31
EP1714651A1 (en) 2006-10-25
IL144216A (en) 2007-07-04
RU2006135205A (ru) 2008-04-10
KR20020002379A (ko) 2002-01-09
JP2002535367A (ja) 2002-10-22
WO2000044378A1 (en) 2000-08-03
NO20013459D0 (no) 2001-07-12
SK10522001A3 (sk) 2001-12-03
AU766453C (en) 2004-11-25
NO20013459L (no) 2001-09-05
AU2439700A (en) 2000-08-18
EP1146872A1 (en) 2001-10-24
EP1146872B1 (en) 2006-06-21
DE60028928T2 (de) 2007-01-04
ES2265910T3 (es) 2007-03-01
DE60028928D1 (de) 2006-08-03
RU2345790C2 (ru) 2009-02-10
PT1146872E (pt) 2006-10-31
DK1146872T3 (da) 2006-10-16
AU766453B2 (en) 2003-10-16
HK1041808A1 (en) 2002-07-26
HUP0105199A3 (en) 2004-11-29
NZ513039A (en) 2003-11-28
HUP0105199A2 (hu) 2002-04-29
CZ20012682A3 (cs) 2001-10-17
BR0007686A (pt) 2001-11-06
KR100674053B1 (ko) 2007-01-25
PL197161B1 (pl) 2008-03-31
HK1041808B (en) 2007-01-19
CY1105257T1 (el) 2010-03-03
CA2360691A1 (en) 2000-08-03
CN1337879A (zh) 2002-02-27
IL144216A0 (en) 2002-05-23
RU2298405C2 (ru) 2007-05-10

Similar Documents

Publication Publication Date Title
CY1106697T1 (el) Ν-υποκατεστημενες υδρομορφονες και η χρηση αυτων
DK1588706T3 (da) Valsartantablet
AU2002226365A1 (en) Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction
NO963064D0 (no) Behandling av normotensive glaukoma med angiotensin-II-antagonister
CY1106365T1 (el) Συνδυασμος ενος αναστολεα pde και ενος ανταγωνιστη υποδοχεων λευκοτριενιου
EP1413201A3 (en) Use of neuronal sodium channel antagonists for the control of ectoparasites in homeothermic animals
IL144216A0 (en) Use of angiotensin ii receptor antagonists for treating acute myocardial infarction
ATE295183T1 (de) Mittel zur linderung von juckreiz, enthaltend pgd2- antagonisten
EE200100520A (et) N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena
MXPA04008460A (es) Composiciones farmaceuticas de un inhibidor de pde4 o pde3/4 y un antagonista de receptor de histamina.
MY135441A (en) Therapeutic treatment
AP2002002501A0 (en) Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
AP1534A (en) Vitronectin receptor antagonists.
EP1537875A4 (en) MEANS FOR THE PREVENTION / TREATMENT OF ARTERIOSCLEROSIS
BR0000486A (pt) Antagonistas do neuropeptìdeo y
PT896822E (pt) 4-aminopirrolo (3,2-d)pirimidinas como antagonistas do receptor de neuropeptideo y
NO20033634L (no) GLyT-1-inhibitorer
EA200401617A1 (ru) Комбинация nmda-антагониста и ингибиторов ацетилхолинэстеразы для лечения болезни альцгеймера
BR0311881A (pt) Combinações de inbidores de pde-v e antagonistas de nk1 para o tratamento de depressão
ZA200405437B (en) Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for the prevention or treatment of pathogenic conditions.
NO981188D0 (no) 5-HT3-reseptorantagonister for dyskinesi
EP1095655A3 (en) NK-1 receptor antagonists and eletriptan for the treatment of migraine